Kezar Life Sciences
South San Francisco, CA, US· latest recorded location
KEZAR LIFE SCIENCES is named on 10 US grants and 14 published applications in this corpus. Its most frequent classification is C07D (Heterocyclic compounds).
- Granted patents
- 10
- Published applications
- 14
- Inventors
- 12
- Granted in 2026 so far
- 1
- Most recent grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2019 | 0 | 2 |
| 2020 | 2 | 1 |
| 2021 | 0 | 4 |
| 2022 | 3 | 3 |
| 2023 | 1 | 3 |
| 2024 | 2 | 0 |
| 2025 | 1 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 24 documents
Recent patents
- Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors14 Apr 2026US 12,600,711 B2
- Immunoproteasome inhibitor formulations15 Jul 2025US 12,357,638 B2
- Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof7 May 2024US 11,976,053 B2
- Crystalline salts of peptide epoxyketone immunoproteasome inhibitor6 Feb 2024US 11,891,383 B2
- Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors14 Feb 2023US 11,578,055 B2
- Sec61 inhibitors and use thereof29 May 2025US 2025/0171434 A1
- Protein secretion inhibitors14 Sep 2023US 2023/0286973 A1
- Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof4 May 2023US 2023/0135100 A1
- Crystalline salts of peptide epoxyketone immunoproteasome inhibitor6 Apr 2023US 2023/0106656 A1
- Triazacyclododecansulfonamide (tcd)-based protein secretion inhibitors22 Dec 2022US 2022/0402891 A1
Most cited
By later US patents